OA06533A - Dérivés de la pyrimidine, procédés pour leur préparation, compositions pharmaceutiques contenant ces composés et leur utilisation thérapeutique. - Google Patents

Dérivés de la pyrimidine, procédés pour leur préparation, compositions pharmaceutiques contenant ces composés et leur utilisation thérapeutique.

Info

Publication number
OA06533A
OA06533A OA57113A OA57113A OA06533A OA 06533 A OA06533 A OA 06533A OA 57113 A OA57113 A OA 57113A OA 57113 A OA57113 A OA 57113A OA 06533 A OA06533 A OA 06533A
Authority
OA
OAPI
Prior art keywords
compounds
processes
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
OA57113A
Other languages
English (en)
Inventor
Dr Adrian Marxer
Dr Kurt Eichenberger
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of OA06533A publication Critical patent/OA06533A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA57113A 1979-05-18 1980-05-17 Dérivés de la pyrimidine, procédés pour leur préparation, compositions pharmaceutiques contenant ces composés et leur utilisation thérapeutique. OA06533A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH466979 1979-05-18

Publications (1)

Publication Number Publication Date
OA06533A true OA06533A (fr) 1981-07-31

Family

ID=4280399

Family Applications (1)

Application Number Title Priority Date Filing Date
OA57113A OA06533A (fr) 1979-05-18 1980-05-17 Dérivés de la pyrimidine, procédés pour leur préparation, compositions pharmaceutiques contenant ces composés et leur utilisation thérapeutique.

Country Status (21)

Country Link
EP (1) EP0019811A1 (fr)
JP (1) JPS55154971A (fr)
KR (1) KR830002757A (fr)
AR (1) AR228256A1 (fr)
AU (1) AU5848480A (fr)
DD (1) DD150609A5 (fr)
DK (1) DK214480A (fr)
ES (1) ES8104279A1 (fr)
FI (1) FI801600A7 (fr)
GB (1) GB2052487B (fr)
GR (1) GR68453B (fr)
IE (1) IE49803B1 (fr)
IL (1) IL60086A (fr)
MA (1) MA18829A1 (fr)
NO (1) NO801469L (fr)
NZ (1) NZ193730A (fr)
OA (1) OA06533A (fr)
PL (1) PL224313A1 (fr)
PT (1) PT71251A (fr)
ZA (1) ZA802909B (fr)
ZW (1) ZW11880A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) * 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
DE3829469A1 (de) * 1988-08-31 1990-03-01 Bayer Ag Verfahren zur herstellung von substituierten n-azinyl-n'-sulfonyl-isothioharnstoffen und n-azinyl-iminodithiokohlensaeure-s,s-diester als zwischenprodukte zu ihrer herstellung
AU9302298A (en) * 1997-09-03 1999-03-22 Eli Lilly And Company Pyrimidine derivatives
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2266258T3 (es) 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
EP1345925B1 (fr) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Composes de pyrazole presentant une grande utilite comme inhibiteurs de proteine kinase
CA2672805A1 (fr) * 2001-01-31 2002-08-08 H. Lundbeck A/S Derives de la pyrimidine
EA200401120A1 (ru) 2002-03-13 2005-02-24 Еуро-Селтик С. А. Арилзамещенные пиримидины и их применение
EP1485380B1 (fr) 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines inhibitrices des proteines kinases
AU2003214110A1 (en) * 2002-03-15 2003-09-29 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
ES2273043T3 (es) 2002-08-02 2007-05-01 Vertex Pharmaceuticals Incorporated Composiciones de pirazol utiles como inhibidores de gsk-3.
WO2004072029A2 (fr) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs de proteine kinases
CA2619517A1 (fr) 2005-08-18 2007-02-22 Michael Mortimore Inhibiteurs de pyrazine kinases
WO2007056163A2 (fr) 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines utiles en tant qu'inhibiteurs de kinases
MX2009004807A (es) 2006-11-02 2009-06-15 Vertex Pharma Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
JP2010513567A (ja) 2006-12-19 2010-04-30 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なアミノピリミジン
ATE526328T1 (de) 2007-03-09 2011-10-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
WO2008112646A1 (fr) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Utilisation des aminopyridines comme inhibiteurs de protéines kinases
WO2008112642A1 (fr) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines utiles en tant qu'inhibiteurs des protéines kinases
CA2683785A1 (fr) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines utilisees en tant qu'inhibiteurs de kinases
MX2009011812A (es) 2007-05-02 2010-01-14 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
CA2685876A1 (fr) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles et pyrazoles qui s'utilisent comme inhibiteurs de kinase
AR067762A1 (es) 2007-07-31 2009-10-21 Vertex Pharma Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
KR20110050549A (ko) 2008-09-03 2011-05-13 버텍스 파마슈티칼스 인코포레이티드 공-결정 및 이를 포함하는 제약 제제
AU2009333559B2 (en) * 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2022101435A1 (fr) * 2020-11-12 2022-05-19 3Z Ehf Nouveaux traitements du trouble du déficit de l'attention/hyperactivité
CN121494792A (zh) * 2026-01-14 2026-02-10 山东国邦药业有限公司 一种5-甲氧基-4,6-二羟基嘧啶的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754832A (fr) * 1969-08-14 1971-02-15 Beecham Group Ltd Iminazolines

Also Published As

Publication number Publication date
PL224313A1 (fr) 1981-02-13
ES491514A0 (es) 1981-04-16
IL60086A0 (en) 1980-07-31
GB2052487B (en) 1983-05-11
GR68453B (fr) 1981-12-30
NO801469L (no) 1980-11-19
IL60086A (en) 1984-03-30
MA18829A1 (fr) 1980-12-31
ES8104279A1 (es) 1981-04-16
AR228256A1 (es) 1983-02-15
FI801600A7 (fi) 1981-01-01
IE801023L (en) 1980-11-18
PT71251A (en) 1980-06-01
DD150609A5 (de) 1981-09-09
GB2052487A (en) 1981-01-28
ZW11880A1 (en) 1980-12-17
DK214480A (da) 1980-11-19
KR830002757A (ko) 1983-05-30
AU5848480A (en) 1980-11-20
IE49803B1 (en) 1985-12-25
ZA802909B (en) 1981-05-27
EP0019811A1 (fr) 1980-12-10
NZ193730A (en) 1982-12-21
JPS55154971A (en) 1980-12-02

Similar Documents

Publication Publication Date Title
OA08647A (fr) Dérivés d'imidazole, procédés pour leur préparation et composition pharmaceutique les contenant.
DZ473A1 (fr) Dérivés de l'acide cis-endo-2-azabicyclo/3,3,o/-octane-3-carboxylique, procédé pour leur préparation, agents contenant ces dérivés et leur utilisation.
OA07124A (fr) Dipeptides substitués, procédés pour leur préparation et compositions pharmaceutiques les contenant et leur utilisation pour l'inhibition de l'encéphalinase.
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA18829A1 (fr) Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
SE7900685L (sv) 9-deoxi-9a-metylenisosterer av pgiŸ2 och forfarande for framstellning av dem
OA07097A (fr) Nouveaux dérivés d'arylphényléther utiles comme microbicides, procédé pour leur préparation et leur utilisation.
DZ712A1 (fr) Nouveaux dérivés de 2-2 iminobisethanol utiles comme médecaments, intermédiaires pour leur préparation et procédés pour la préparation de ces dérivés et intermédiaires.
DZ418A1 (fr) Dérivés de céphalosporine, leur procédé de préparation et leur application thérapeutique.
FR2422620A1 (fr) Derives du stilbene, leur preparation et leur application en tant que medicaments
OA05577A (fr) Procédé de préparation de compositions pharmaceutiques renfermant des pyréthrinoïdes.
FR2708606B1 (fr) Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2445319A1 (fr) Derives de pyridine, procedes pour leur preparation et compositions pharmaceutiques les contenant
OA07699A (fr) Dérivés de la furo-(3,4-c)-pyridine leur préparation et compositions thérapeutiques contenant ces dérivés.
OA07236A (fr) Dérivés de la triazine, procédés pour leur préparation, et compositions pharmaceutiques comportant ces dérivés.
OA06651A (fr) Nouveaux dérivés de la pipéridylbenzimidazolinone, leurs procédés de préparation, les compositions pharmaceutiques les renfermant.
BE885385A (fr) Derives de d-6-n-propylergolines, leur procede de preparation et compositions pharmaceutiques en contenant
ZA783086B (en) Benzodiazepine compounds processes for their preparation,and pharmaceutical compositions thereof
OA06951A (fr) Dérivés de la thiéno-pyridinone, leur procédé de préparation et leur application thérapeutique.
OA07525A (fr) Dérivés d'acides-animés, leur préparation et utilisation ainsi que les compositions contenant ces dérivés.
IL65843A (en) Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
OA09442A (fr) Dérivés de la thiéno-triazolo-diazépine, un procédé pour leur préparation et compositions thérapeutiques en contenant.
OA07390A (fr) Nouveaux dérivés de carbapenem, compositions pharmaceutiques les contenant, composés intermédiaires pour leur préparation, et leurs procédés de production.
ZA783084B (en) Benzodiazepine compounds processes for their preparation,and pharmaceutical compositions thereof